Purpose: This study aimed to report the real-world outcomes of intravesical gemcitabine for bacillus Calmette–Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer (HR-NMIBC) in Korean patients who were unable or unwilling to undergo radical cystectomy (RC). Materials and Methods: This retrospective study included 131 patients (median age, 69 years; 88.5% men) treated with intravesical gemcitabine for BCG-unresponsive HR-NMIBC at nine centers between May 2019 and April 2022. The primary endpoint was 1-year recurrence-free survival (RFS). The secondary endpoints included factors influencing RFS, progression-free survival (PFS), cystectomy- free survival, cancer-specific survival (CSS), overall survival (OS), and safety. Survival analysis was performed using the Kaplan-Meier method, and risk factors for recurrence were assessed using Cox regression models. Results: Patients were followed up for a median duration of 25 months, with carcinoma in situ (CIS) in 41.9% of the patients. The 1-year and 2-year RFS rates were 68% and 42%, while the 1-year and 2-year PFS rates were 87% and 77%, respectively. No significant factors influencing RFS were identified. Seventeen patients underwent RC during a median follow-up of 16 months, with the condition in three patients progressing to muscle-invasive disease on final pathological analysis. The 2-year CSS and OS rates were 98% and 97%, respectively. Intravesical gemcitabine was well-tolerated, with only seven patients (5.3%) unable to complete the full induction course. Conclusion Our research highlights the potential of intravesical gemcitabine as a viable bladder-sparing treatment option for BCG-unresponsive HR-NMIBC, providing real-world evidence on its safety, efficacy, and tolerability.

Background: This study assessed 10-year changes in the proportion and epidemiology of work-related burns among inpatients at a single institution; as an institutional proportion, results reflect within-center surveillance. Methods: Burn inpatients admitted in 2016–2025 (n=5,074), including work-related burns (n=535), were retrospectively reviewed. Annual proportions were calculated. Because proportions dropped during COVID-19 (2020–2022), these years were excluded from the primary trend analysis. Period differences were tested with two-proportion tests and an overall 2×3 chi-square test; trends excluding 2020–2022 were evaluated with linear regression. Results: Work-related burns accounted for 10.5% (535/5,074). The proportion decreased in 2020–2022 versus 2016–2019 (7.7% vs. 10.9%; P=0.002) and increased in 2023–2025 versus 2020–2022 (13.1% vs. 7.7%; P<0.001); overall period differences were significant (chi-square P<0.001). Excluding 2020–2022, the proportion increased by +0.34 percentage points/year (95% confidence interval, 0.05–0.63; P=0.029). Scalds (53.6%) and electrical burns (18.5%) predominated. Mean burn total body surface area (TBSA) was 5.9%±9.2%, with 83.7% <10% TBSA; 78.9% were second-degree burns. Surgery was performed in 292 (54.6%), most commonly split-thickness skin grafting (STSG; n=150) or STSG with acellular dermal matrix (n=92). The highest incidence occurred in summer (33.3%). Conclusion After excluding 2020–2022, the institutional proportion of work-related burns increased over time despite declining total burn admissions. This reflects a relative shift in case-mix, not population-level incidence; explanations such as changing exposures or improved reporting/compensation are hypothesis-generating.

The anticancer drugs have evolved significantly, spanning molecular targeted therapeutics (MTTs), immune checkpoint inhibitors (ICIs), chimeric antigen receptor T-cell (CAR-T) therapy, and antibody-drug conjugates (ADCs). Complications associated with these drugs vary widely based on their mechanisms of action. MTTs that target angiogenesis can often lead to complications related to ischemia or endothelial damage across various organs, whereas non-anti-angiogenic MTTs present unique complications derived from their specific pharmacological actions. ICIs are predominantly associated with immunerelated adverse events, such as pneumonitis, colitis, hepatitis, thyroid disorders, hypophysitis, and sarcoid-like reactions. CAR-T therapy causes unique and severe complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. ADCs tend to cause complications associated with cytotoxic payloads. A comprehensive understanding of these drug-specific toxicities, particularly using medical imaging, is essential for providing optimal patient care. Based on this knowledge, radiologists can play a pivotal role in multidisciplinary teams. Therefore, radiologists must stay up-to-date on the imaging characteristics of these complications and the mechanisms underlying novel anticancer drugs.

The anticancer drugs have evolved significantly, spanning molecular targeted therapeutics (MTTs), immune checkpoint inhibitors (ICIs), chimeric antigen receptor T-cell (CAR-T) therapy, and antibody-drug conjugates (ADCs). Complications associated with these drugs vary widely based on their mechanisms of action. MTTs that target angiogenesis can often lead to complications related to ischemia or endothelial damage across various organs, whereas non-anti-angiogenic MTTs present unique complications derived from their specific pharmacological actions. ICIs are predominantly associated with immunerelated adverse events, such as pneumonitis, colitis, hepatitis, thyroid disorders, hypophysitis, and sarcoid-like reactions. CAR-T therapy causes unique and severe complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. ADCs tend to cause complications associated with cytotoxic payloads. A comprehensive understanding of these drug-specific toxicities, particularly using medical imaging, is essential for providing optimal patient care. Based on this knowledge, radiologists can play a pivotal role in multidisciplinary teams. Therefore, radiologists must stay up-to-date on the imaging characteristics of these complications and the mechanisms underlying novel anticancer drugs.

The anticancer drugs have evolved significantly, spanning molecular targeted therapeutics (MTTs), immune checkpoint inhibitors (ICIs), chimeric antigen receptor T-cell (CAR-T) therapy, and antibody-drug conjugates (ADCs). Complications associated with these drugs vary widely based on their mechanisms of action. MTTs that target angiogenesis can often lead to complications related to ischemia or endothelial damage across various organs, whereas non-anti-angiogenic MTTs present unique complications derived from their specific pharmacological actions. ICIs are predominantly associated with immunerelated adverse events, such as pneumonitis, colitis, hepatitis, thyroid disorders, hypophysitis, and sarcoid-like reactions. CAR-T therapy causes unique and severe complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. ADCs tend to cause complications associated with cytotoxic payloads. A comprehensive understanding of these drug-specific toxicities, particularly using medical imaging, is essential for providing optimal patient care. Based on this knowledge, radiologists can play a pivotal role in multidisciplinary teams. Therefore, radiologists must stay up-to-date on the imaging characteristics of these complications and the mechanisms underlying novel anticancer drugs.

The anticancer drugs have evolved significantly, spanning molecular targeted therapeutics (MTTs), immune checkpoint inhibitors (ICIs), chimeric antigen receptor T-cell (CAR-T) therapy, and antibody-drug conjugates (ADCs). Complications associated with these drugs vary widely based on their mechanisms of action. MTTs that target angiogenesis can often lead to complications related to ischemia or endothelial damage across various organs, whereas non-anti-angiogenic MTTs present unique complications derived from their specific pharmacological actions. ICIs are predominantly associated with immunerelated adverse events, such as pneumonitis, colitis, hepatitis, thyroid disorders, hypophysitis, and sarcoid-like reactions. CAR-T therapy causes unique and severe complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. ADCs tend to cause complications associated with cytotoxic payloads. A comprehensive understanding of these drug-specific toxicities, particularly using medical imaging, is essential for providing optimal patient care. Based on this knowledge, radiologists can play a pivotal role in multidisciplinary teams. Therefore, radiologists must stay up-to-date on the imaging characteristics of these complications and the mechanisms underlying novel anticancer drugs.

The anticancer drugs have evolved significantly, spanning molecular targeted therapeutics (MTTs), immune checkpoint inhibitors (ICIs), chimeric antigen receptor T-cell (CAR-T) therapy, and antibody-drug conjugates (ADCs). Complications associated with these drugs vary widely based on their mechanisms of action. MTTs that target angiogenesis can often lead to complications related to ischemia or endothelial damage across various organs, whereas non-anti-angiogenic MTTs present unique complications derived from their specific pharmacological actions. ICIs are predominantly associated with immunerelated adverse events, such as pneumonitis, colitis, hepatitis, thyroid disorders, hypophysitis, and sarcoid-like reactions. CAR-T therapy causes unique and severe complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. ADCs tend to cause complications associated with cytotoxic payloads. A comprehensive understanding of these drug-specific toxicities, particularly using medical imaging, is essential for providing optimal patient care. Based on this knowledge, radiologists can play a pivotal role in multidisciplinary teams. Therefore, radiologists must stay up-to-date on the imaging characteristics of these complications and the mechanisms underlying novel anticancer drugs.

Purpose: Although chemical burns account for a small proportion of all burn injuries, they remain clinically significant because of the risk of progressive tissue necrosis caused by residual agents. These injuries require prompt removal of the offending substance and timely wound coverage when indicated. This study aims to present surgical treatment strategies, focusing on necessity of early escharectomy and selection of appropriate wound coverage, in patients with chemical burns.M ethods: A retrospective review was conducted of 66 patients with chemical burns admitted to the Department of Plastic and Reconstructive Surgery at Hanil General Hospital between 2019 and 2024. Data collected included causative agents, wound location, total body surface area (TBSA), burn depth, surgical interventions, and postoperative complications. Surgical procedures, such as early or delayed escharectomy, split-thickness skin grafting (STSG), STSG with an acellular dermal matrix (ADM), full-thickness skin grafting (FTSG), and local flap coverage, were selected according to the wound characteristics. Results: Of the 66 patients, 48 underwent surgical treatment, and 18 were managed conservatively. Among the surgical cases, early excision (escharectomy) was performed in 10 patients (20.8%), whereas delayed excision was performed in 38 patients (79.2%). Wound coverage procedures were performed in 30 patients (62.5%). Conclusion Early excision of necrotic tissue and appropriate wound coverage is associated with favorable outcomes in patients with chemical burns.

Background: High-voltage electrical burn injuries, though relatively uncommon, often cause extensive deep-tissue destruction and severe functional impairment. Although standard reconstructive algorithms are well established, simultaneous bilateral hand involvement in a patient with systemic comorbidity poses a unique reconstructive challenge requiring individualized flap selection and staged planning.Case: A 56-year-old man sustained bilateral high-voltage arc burns (22,900 V) on the bilateral hands. The left hand was identified as the entry site and the right hand as the exit site. Because of poor graft take after split-thickness skin grafting (STSG) with an acellular dermal matrix (ADM) and recurrent tendon exposure, a tailored reconstructive strategy was implemented.Negative-pressure wound therapy (NPWT) was used to enhance granulation, followed by a pedicled groin flap for the dominant right hand and sequential local advancement flaps with continued NPWT for the left. Both flaps survived completely achieving stable coverage and restoration of near normal motion (range of motion: right 0~90°, left 0~95°) at 3 months. Conclusion This case highlights that even in the absence of microsurgical options, staged reconstruction combining NPWT, pedicled groin flap, and local flaps can achieve durable wound closure and functional recovery in medically compromised patients with bilateral hand electrical burns. The key clinical message is that flap selection should be individualized based on wound characteristics, systemic condition, and the balance between surgical risk and long-term function.

The Korean Society of Infectious Diseases has been regularly publishing guidelines for adult immunization since 2007. Following the release of coronavirus disease 2019 (COVID-19) vaccination recommendations in 2023, significant changes have occurred due to the emergence of new variant strains and the waning immunity from previous vaccinations. This article provides a comprehensive update as of November 2024, incorporating the latest evidence and guidelines. Focusing on the 2024–2025 season, this article reviews vaccines currently authorized in Korea and assesses their effectiveness against the predominant JN.1 lineage variants. The updated recommendations prioritize high-risk groups, including adults aged 65 and older, individuals with underlying medical conditions, residents of facilities vulnerable to infection, pregnant women, and healthcare workers, for vaccination with updated vaccines targeting the JN.1 strain. Additionally, COVID-19 vaccination is available for all individuals aged 6 months and older. For most adults, a single-dose strategy is emphasized, while tailored schedules may be recommended for immunocompromised individuals. This update aims to optimize vaccination strategies in Korea to ensure comprehensive protection for high-risk populations.